Your session is about to expire
← Back to Search
GVAX pancreas vaccine for Pancreatic Cancer
Study Summary
This trial is testing a new vaccine for pancreatic cancer.
- Pancreatic Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 56 Patients • NCT00389610Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is enrollment still available for this experiment?
"According to the official record on clinicaltrials.gov, this clinical trial is not presently enrolling patients. This trial was initially posted in September of 2006 and recently edited in September 2022 - although it is currently inactive, 699 other studies are actively recruiting participants at this time."
What are the eligibility requirements for participating in this clinical research?
"Aspirants of this medical trial must have malignant neoplasm of the pancreas and be within 18 to 120 years old. 56 people are being sought out for enrollment."
Does this clinical trial accept individuals above the age of 20?
"The requirements for participation in this medical trial dictate that the patient's age must be somewhere between 18 to 120 years. Additionally, there are 13 trials targeting under-18s and 696 studies focused on people aged 65 or over."
What is the regulatory status of GVAX pancreas vaccine?
"Based on the current amount of information available, the safety of GVAX pancreas vaccine is rated a 2 by our team at Power. This trial is in its second phase and there are data that suggest it has some level of security but none to confirm efficacy."
Share this study with friends
Copy Link
Messenger